Skip to content

Software for COVID19 Detection from Chest X-Ray, CT or Ultrasonography

Real-Time Artificial Intelligence based COVID detection from Chest X-Ray, Ultrasound or CT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/07/026351
Enrollment
1000
Registered
2020-07-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

PurplAS IT Services Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: This study poses no additional health risk associated with standard Chest X-Ray, CT or Ultrasound procedures. The medical information that will be collected from you if you take part in this study includes: Your chest X-Ray, CT or Ultrasound Scan/Video. You may be asked to take an RT-PCR or any other COVID19 confirmatory test. Your Health data may be recorded for presence of any pre-existing diseases

Exclusion criteria

Exclusion criteria: Patients with conditions preventing them from undergoing standard chest X-Ray, CT or Ultrasound procedures.

Design outcomes

Primary

MeasureTime frame
The entire project aims to develop a market ready Artificial Intelligence based object recognition software capable of working on Real-time live Chest Radio-Imaging data like CT Scans, Ultrasound, and X-Ray as well as integrate the same with hardware prototype(s) capable of running the software.Timepoint: 2 Sub-phases: Data Collection & Testing: 4 weeks (Sensitivity Benchmarks will be outcome) Testing & Validation: 6 weeks (replication of Outcome/Sensitivity Benchmarks of week 4 over clinical scenario)

Secondary

MeasureTime frame
Collection of Chest Radio-Imaging data like CT Scans, Ultrasound, and X-Ray from multiple COVID-19 patients and Refining of AI models for COVID19 detectionTimepoint: 4 weeks from start of trials;Test and validate sensitivity and reliability of COIVD19 identification in Controlled clinical scenarioTimepoint: 6 weeks from end of Secondary Outcome 1

Countries

India

Contacts

Public ContactAbhishek Biswas

PurplAS IT Services Pvt. Ltd.

abhishek@purpletech.in8585010011

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026